Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GNPAT | O15228 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468749 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| Hydrogen Sulfide SCHEMBL27584727 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| Acetic Acid SCHEMBL27748313 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| Methane SCHEMBL5044798 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| Methane SCHEMBL5044803 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL6841658 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL6896498 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL19183299 | 0.84 | KDM4E (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL16745724 | 0.84 | GNPAT (0.62) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7719184 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119799606-A | Recombinant escherichia coli for producing heme and derivative compound thereof and preparation method thereof | 微元合成生物技术(北京)有限公司 | 2025-04-11 | — | — | CN | claimed |
| EP-3504318-B1 | METHOD OF IMPROVING METHYLTRANSFERASE ACTIVITY | UNIV DANMARKS TEKNISKE (DK) | 2025-04-09 | — | — | EP | claimed |
| CN-119555822-A | Urine metabolism marker composition for diagnosis of cancer seeds of pan-cancer, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2024179537-A1 | METHOD FOR DIRECTLY PREPARING L-GLUFOSINATE FROM L-HOMOSERINE | 湖南利尔生物科技有限公司 | 2024-09-06 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-4182300-A1 | IMPROVED METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS | ARKEMA FRANCE (FR) | 2023-05-24 | — | — | EP | claimed |
| US-20230080311-A1 | Method of improving methyltransferase activity | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-03-16 | — | — | US | claimed |
| CN-115725537-A | Aspartokinase mutant and application thereof in producing L-homoserine | 中国科学院天津工业生物技术研究所 | 2023-03-03 | — | — | CN | claimed |
| EP-2751276-B1 | PREPARATION PROCESS OF L-METHIONINE | ARKEMA FRANCE (FR) | 2023-01-25 | — | — | EP | claimed |
| US-11124813-B2 | N-acetyl homoserine | EVONIK OPERATIONS GMBH (DE) | 2021-09-21 | — | — | US | claimed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20060063827-A1 | Systemic administration of therapeutic amino acids and N-acetylamino acids | YU RUEY J | 2006-03-23 | — | — | US | claimed |
| EP-1633851-A2 | METHODS AND COMPOSITIONS FOR AMINO ACID PRODUCTION | Microbia, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050255568-A1 | Methods and compositions for amino acid production | NOVUS INTERNATIONAL, INC. | 2005-11-17 | — | — | US | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2004108894-A2 | METHODS AND COMPOSITIONS FOR AMINO ACID PRODUCTION | MICROBIA, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124813-B2 | N-acetyl homoserine | ACAT2, PSAT1, ACSS2 | SMN1; SMN2 4611/4885KDM4E 3791/4885MAPT 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.